Jing Shan Lim
About Jing Shan Lim
Jing Shan Lim is a Research Scientist (II) at Lucence, with a strong background in cancer biology and biotechnology. He has contributed to various research projects and clinical trials while actively engaging in the life sciences community through events and outreach initiatives.
Current Role at Lucence Health
Jing Shan Lim currently serves as a Research Scientist (II) at Lucence Health, a position held since 2020. In this role, Lim contributes to the development and implementation of innovative research projects in the field of cancer diagnostics. Lim's expertise in molecular and cellular biology plays a crucial role in advancing the company's mission to improve patient outcomes through precision medicine.
Previous Experience at Lucence Health
Prior to the current role, Jing Shan Lim worked at Lucence Health as a Research Scientist for seven months in 2019. During this time, Lim was involved in various research initiatives that focused on enhancing diagnostic techniques in oncology, contributing to the company's research objectives.
Background in Biotech Connection Singapore
Jing Shan Lim served as Events Lead at Biotech Connection Singapore from 2017 to 2019. In this capacity, Lim was actively involved in organizing events aimed at promoting biotech and healthcare outreach. Lim also worked as a Consultant for one month in 2018, contributing insights and expertise to various projects within the organization.
Academic Qualifications
Jing Shan Lim holds a Doctor of Philosophy (Ph.D.) in Cancer Biology from Stanford University, where Lim studied from 2010 to 2016. Prior to this, Lim earned a Bachelor of Science (BSc) in Molecular and Cellular Biology from the University of Illinois at Urbana-Champaign, completing the degree from 2006 to 2009. This strong academic foundation supports Lim's research endeavors in the field of oncology.
Research Contributions and Publications
Jing Shan Lim has published several research papers in top scientific journals, contributing to the body of knowledge in cancer diagnostics and treatment. Notably, Lim co-authored a publication on liquid biopsy in combination with PET/CT for lung cancer diagnosis in small nodules, which was published in the Journal of Clinical Oncology in 2023. This work reflects Lim's commitment to advancing clinical practices through research.